Entrada Therapeutics, Inc. announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable. The primary objective of Entrada's Phase 1 clinical trial, which is being conducted in the United Kingdom, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers, with a target enrollment of approximately 40 participants. The trial will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.

ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within its Duchenne franchise from Entrada's growing pipeline of EEV-therapeutics. Each EEV-PMO therapeutic candidate has an oligonucleotide sequence designed and optimized for the specific subpopulation of interest. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, ability to recruit for and complete a healthy volunteer trial for ENTR-601-44 In the United Kingdom with first subject dosed in September 2023, expectations regarding the timing of data from its Phase 1 trial for ENTR-601, the potential of its EEV product candidates and EEV platform, and the continued development and advancement of ENTR- 601-44 and EEV-45 for the treatment of Duchenne, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.